Menu hamburgerclose

Advancing Peritoneal Dialysis (PD)

Millions of patients worldwide depend on dialysis to survive. Our novel fluid, PDprotec®, is designed to improve the outcomes of this treatment and reduce the burden of kidney failure for patients and health care providers.
Zytoprotec assumes that the number of dialysis patients will continue to increase significantly for many years to come. An estimated 90% of dialysates are sugar-based. According to Zytoprotec estimates, the global market for dialysis fluids will have a volume of more than 3 EUR billion in 2021 (gross annual sales).

> more information

PDprotec®key advantages

Improved clinical outcome

Prolonged time for which patients can benefit from PD

Increase market share of PD in dialysis overall

The Zytoprotec success story

Beginning of
Phase III

> read more

  • Product prepared to enter pivotal Phase III trial 
  • Outstanding safety and efficacy demonstrated for PDprotec® in Phase I/II and Phase II studies
  • Orphan Drug designation granted by FDA
  • Follow-on PD fluid ICOprotec® ready for clinical development

PDprotec® NEWS

New: Capital market prospectus 2022

New: Capital market prospectus 2022

For an investment in a share in the Private Limited Company (GmbH) of the issuer to be newly issued and held in trust and/or in a new atypical silent partnership with the issuer, to be entered into in trust, investors can obtain subscription forms online on the platform www.join-zytoprotec.at. In both investments the minimum subscription is 5,000 EUR. The subscription volume of both investment will amount to less than 5 mio. EUR. The offer period starts on 17th of October 2022 and will end with the expiry of 16th of October 2023. Click here to find our 2022 capital market prospectus (only german). 

Zytoprotec Phase II Peritoneal Dialysis Study: Last Patient Out

Vienna, Europe, November 14, 2016 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids with cytoprotective properties, announced today that the last patient has completed treatment in a Phase II study with its lead product, PDprotec®. The Company expects results of this trial to be available in the first quarter of 2017.

> read more

Zytoprotec's Novel Dialysis Product Meets Both Endpoints in Phase II Study

Vienna, Europe, June 9, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today the highly promising outcome of the Phase II study of its peritoneal dialysis fluid PDprotec®. In this double-blind, placebo-controlled cross-over study, the two primary endpoints were successfully met.

> read more

> show all

Award-winning science
and world-class
clinical research

To improve the lives of patients.

Science and Technology

The development of PDprotec® has been advanced by Zytoprotec’s own scientists and clinical experts and by the expertise and support provided by global leaders in the field of PD represented in our Scientific Advisory Board.

Scientific Advisory Board

A clear step forward in next generation PD solutions."*
Prof. Dr. Nicholas Topley

They say a bit of stress is good for you – Zytoprotec research shows nicely how you can incorporate this principle into clinical practice of PD."
Prof. Dr. Janusz Witowski

Targeting peritoneal membrane barrier and transport function by PDprotec® improves PD efficacy and biocompatibility and should improve PD substantially and ultimately patient long-term outcome."*
Prof. Dr. Claus Peter Schmitt, Heidelberg

A big step toward the reservation of peritonea membrane in PD patients. An attractive approach to preserve the peritoneal membrane, complementary to the efforts to improve fluid biocompatibility, is the use of additives protecting the mesothelium. In this context, Zytoprotec, through the wise combination of basic and clinical research, has developed novel PD fluids that mitigate peritoneal damage and, as a consequence, reduce systemic side-effects of dialysis treatment."*
Prof. Dr. Manuel Lopez Cabrera

The phase2 data suggest that PDprotec will restore mesothelial integrity and inflammatory responses, providing a potential step change for PD. A sufficiently powered phase 3 study that has impacts on clinically meaningful endpoints is now required.“*
Prof. Dr. Simon Davies, Keele, United Kingdom

*Quote was made in an e-mail correspondence between the expert and Professor Aufricht